Pitt B, Filippatos G, Agarwal R, et al. - The results revealed that finerenone therapy improved cardiovascular outcomes as compared with placebo among patients with type 2 diabetes and stage 2 to 4 chronic kidney disease (CKD) with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria.

• Researchers randomized a total of 7,437 patients.

• The results showed that in the finerenone group, a primary outcome event occurred in 458 of 3,686 patients (12.4%) and in 519 of 3,666 (14.2%) in the placebo group (hazard ratio, 0.87; 95% confidence interval [CI], 0.76 to 0.98; P=0.03), with the benefit-driven primarily by a lower incidence of hospitalization for heart failure (hazard ratio, 0.71; 95% CI, 0.56 to 0.90) during a median follow-up of 3.4 years among the patients included in the analysis.

• The results found 350 patients (9.5%) and 395 (10.8%) as the secondary composite outcome in the finerenone group and the placebo group respectively (hazard ratio, 0.87; 95% CI, 0.76 to 1.01).

• According to the results, the overall frequency of adverse events did not differ substantially between groups.

• They found a higher incidence of hyperkalemia-related discontinuation of the trial regimen with finerenone (1.2%) than with placebo (0.4%).